On Monday, 13 February, the European Parliament has confirmed the mandate of the Rapporteur to start negotiating its position on the European Chips Act with the Council of the European Union. AmCham EU welcomes this development and praises the efforts made by all the political groups within the European Parliament to build broad consensus on the report. The EU Chips Act will foster investments that the EU urgently needs in innovative semiconductor manufacturing to strengthen Europe’s resilience.
Setting the stage for the Chips Act
On Monday, 13 February, the European Parliament has confirmed the mandate of the Rapporteur to start negotiating its position on the European Chips Act with the Council of the European Union. AmCham EU welcomes this development and praises the efforts made by all the political groups within the European Parliament to build broad consensus on the report. The EU Chips Act will foster investments that the EU urgently needs in innovative semiconductor manufacturing to strengthen Europe’s resilience.
In order to achieve this, we call for the following points to be considered by policymakers during the trilogues.
Firstly, a clearer timeline for state-aid applications approval by the European Commission and fast-track permits procedures in Member States will help timely develop a more geographically diversified, sustainable and resilient semiconductor supply chain in Europe.
Secondly, it will be crucial for some additions to be kept within the final text, such as a definition of ‘crisis’, strong ‘last resort’ safeguards in pillar 3, a narrow list of critical sectors and a ‘right to be heard’ for manufacturers subject to emergency measures.
Thirdly, AmChamEU supports amendments aimed at further strengthening international cooperation with likeminded third countries (i.e. the US) and the robust involvement of industry in the EU Semiconductor Board activities.
AmCham EU stands ready to support EU policymakers and encourages a swift adoption of the Act.
Related items
:focal())
News
5 May 2026
Simplifying the Foreign Subsidies Regulation
With the Foreign Subsidies Regulation (FSR) under review, now is the moment to ensure it delivers on its objectives without creating unnecessary complexity. The FSR plays an important role in addressing distortive foreign subsidies. However, its broad scope and resource-intensive procedures risk undermining its effectiveness.
The current framework creates significant burdens for investors and contracting authorities managing public procurement processes. Changes to the Implementing Regulation alone would only provide limited value. Simplification will require targeted amendments to the primary legislation.
Read more about proposed amendments that would help refocus the FSR on high-risk cases and support the EU’s competitiveness goals.
:focal())
News
4 May 2026
Discussing financial services with policymakers in Paris and Strasbourg
From Monday, 27 to Wednesday, 29 April, AmCham EU travelled to Paris, France and the European Parliament in Strasbourg, France for a series of meetings on EU financial services policy developments. The delegation engaged with representatives from French and European financial authorities, Members of the European Parliament, Accredited Parliamentary Assistants and Group Policy Advisers, to share business perspectives on the EU’s financial services agenda. Discussions focused on how to improve Europe’s competitiveness, deepen capital markets and create the right conditions for innovation in digital finance. Members also highlighted the need for more coherent and interoperable rules that reduce complexity while encouraging long-term investment through risk-based regulation.
:focal())
News
4 May 2026
Discussing healthcare policy priorities in Strasbourg
On Tuesday, 28 to Wednesday, 29 April, AmCham EU travelled to the European Parliament in Strasbourg, France for a series of meetings with policymakers to discuss ongoing EU healthcare policy initiatives. The delegation met with Members of the European Parliament, Accredited Parliamentary Assistants and Group Policy Advisers, to discuss priorities for the EU’s health agenda. This included exchanges on how to strengthen Europe’s life sciences competitiveness and support resilient supply chains. Members also stressed the need for urgent action to simplify overlapping rules and reduce complexity. They underlined that proportionate, risk-based regulation is essential to support innovation. This approach can also help ensure timely patient access to medicines, medical technologies and diagnostics.
Policy priorities
Insights and advocacy driving Europe’s policy agenda. Our priorities support growth, innovation and a stronger transatlantic economy.
Membership
Connecting business and policymakers to strengthen the voice of American companies in Europe.